MT

Molecular Templates IncNASDAQ MTEM Stock Report

Last reporting period 30 Jun, 2024

Updated 25 Nov, 2024

Last price

Market cap $B

0.008

Micro

Exchange

XNAS - Nasdaq

MTEM Stock Analysis

MT

Uncovered

Molecular Templates Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-7/100

Low score

Market cap $B

0.008

Dividend yield

Shares outstanding

56.352 B

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. The company is headquartered in Austin, Texas and currently employs 224 full-time employees. The company went IPO on 2005-02-04. The firm is focused on the discovery and development of biologic therapeutics. The firm's drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit (SLTA) to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases. The Company’s pipeline includes MT-6402, MT-5111, MT-0169, CTLA-4, TROP-2, TIGIT, BCMA and SLAMF-7. MT-6402 is an ETB consisting of a single chain variable fragment (scFv) with affinity for PD-L1, fused to the enzymatically active de-immunized Shiga-like toxin-A subunit (SLTA) and a class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-0169 focuses on targeting CD38, which is a single-chain type II transmembrane glycoprotein.

View Section: Eyestock Rating